Antoine Bejjani, Candrika D Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H Talasaz, John Fanikos, Jean M Connors, Deborah M Siegal, Geoffrey D Barnes, Karlyn A Martin, Dominick J Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S V Elkind, Christian T Ruff, Samuel Z Goldhaber, Harlan M Krumholz, Roxana Mehran, Mary Cushman, John W Eikelboom, Gregory Y H Lip, Jeffrey I Weitz, Renato D Lopes, Behnood Bikdeli
For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in conditions such as embolic stroke of undetermined source...
January 23, 2024: Journal of the American College of Cardiology